Supplementary Figure 4: SYNCRIP is expressed in human AML, and SYNCRIP depletion results in apoptosis and increased myeloid differentiation in AML cell lines.

(a) The graph shows the log₂ expression of SYNCRIP from transcript profiling of bone marrow cells from healthy donors and patients with various types of hematological malignancies, including ALLs, B-ALLs, CLL, MDS, CML and subtypes of AML. Hypodiploid B-ALL, n = 40; ALL with t(1;19), n = 36; ALL with t(12;21), n = 58; B-ALL with t(8;14), n = 13; c-/pre-B-ALL without t(9;22), n = 237; c-/pre-B-ALL with t(9;22), n = 122; pro-B-ALL with t(11q23)/MLL, n = 70; CLL, n = 448; T-ALL, n = 174; MDS, n = 206; CML, n = 76; complex AML, n = 48; AML with inv(16), n = 28; AML MLL, n = 38; AML with a normal karyotype, n = 351; AML with t(15;17), n = 37; AML with t(8;21), n = 40; healthy donors, n = 73. **P < 0.01, ***P < 0.001, ****P < 0.0001, Student’s t test. (Hemaexplorer data for SYNCRIP probe 209024_s_at from the U133 and U133 Plus 2.0 arrays.) (b) qPCR showing SYNCRIP mRNA levels in multiple human AML cell lines and normal cord blood–derived CD34⁺ (CB-CD34⁺) cells. ACTB served as a control housekeeping gene. Relative mRNA level was normalized to the SYNCRIP mRNA level in CB-CD34⁺ cells. (c–f) Immunoblots showing efficient SYNCRIP knockdown in the indicated human AML cell lines. (g) Quantitative summary of CD14^high and CD13^high cells and CD14 and CD13 MFI in MOLM13, NB4 and NOMO-1 cells transduced with control shRNA or shRNAs against SYNCRIP (shRNA 1 and shRNA 2) 4 d after transduction. (h) Representative FACS plots of the cells in Figure 4h. All data represent the means + s.e.m. of at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed t test.